Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | TYR | P14679 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2846164 | 1.00 | TTR (0.58) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL23665770 | 0.88 | TTR (0.58) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL192124 | 0.85 | TTR (0.63) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL5225706 | 0.85 | TTR (0.63) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL192123 | 0.85 | TTR (0.63) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL7298196 | 0.84 | TTR (0.61) | TTRAPPCA12CA1CA2 | |
| SCHEMBL7298203 | 0.84 | TTR (0.61) | TTRAPPCA12CA1CA2 | |
| SCHEMBL13660708 | 0.84 | TUBB1 (0.46) | TTRAPPPTPN1EPHX2TUBB1 | |
| SCHEMBL11222387 | 0.83 | APP (0.73) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL2847488 | 0.83 | TTR (0.59) | TTRAPPPTPN1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080567-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2011-12-20 | — | — | US | disclosed |
| US-20100130556-A1 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED (GB) | 2010-05-27 | — | — | US | disclosed |
| EP-1951701-A2 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED (GB) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007017687-A2 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED (GB) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130556-A1 | EP2 RECEPTOR AGONISTS | PTGER3, PTGER2, CNR2 | TTR 3643/4885APP 4765/4885PTPN1 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.